RankingsPricing
  1. US-listed companies
  2. RedHill Biopharma Ltd.
  3. Financials
  4. Revenue growth (%)

RedHill Biopharma Ltd.RDHL

Market cap
P/E ratio
SummaryFinancials
Period EndRevenue growth (%) YoY (%)
Dec 31, 202423.2-125.91%
Dec 31, 2023-89.4+220.08%
Dec 31, 2022-27.9-184.03%
Dec 31, 202133.3-96.40%
Dec 31, 2020923-3829.41%
Dec 31, 2019-24.7-122.78%
Dec 31, 2018108.6

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)